Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Gilead Buys Its Third Priority Review Voucher, But Is The Mania Over?

Feb 22 2017

• By Derrick Gingery

Priority Review Voucher — Joke Benschop

Related Content

PCSK9 Sponsors Looked For Regulatory Advantages In Race To Market

Dec 21 2015

Sponsors May Race For Rare Pediatric Voucher Designations As Deadline Nears

Dec 23 2016

Sarepta's Eteplirsen Approved After Contentious Internal FDA Debate

Sep 20 2016

Priority Review Vouchers Appear To Be Dropping In Price

Jul 27 2016

US FDA Getting More Money Up Front Under Cures Bill Revisions

Dec 01 2016

Priority Review Voucher Expansion Could Be Bad, Program Creator Says

May 13 2016

Novo Nordisk, Sanofi Insulin Combo Products Clear US Regulatory Hurdles

Nov 22 2016

Keeping Track: Imbruvica Snags First-Line CLL Claim; Gilead TAF Strategy Advances

Mar 07 2016

Review Voucher Program For Rare Pediatric Diseases Should Not Be Reauthorized, US FDA Says

Mar 03 2016

Voucher Does Not Guarantee A Priority Review, FDA Says

Oct 06 2016

Amid Pricing Criticism, Marathon 'Pausing' Emflaza Launch

Feb 13 2017

Marathon's High-Priced Window May Not Stay Open Long

Feb 13 2017

Drug Pricing Bill May Make Six-Month ANDA Review Slower Than Eight-Month Review

Feb 03 2017

Related Companies

Sarepta Therapeutics, Inc.

Gilead Sciences, Inc.

Knight Therapeutics, Inc.

Humanigen, Inc.

BioMarin Pharmaceutical Inc.

Sanofi

Regeneron Pharmaceuticals, Inc.

Amgen, Inc.

Novo Nordisk A/S

Marathon Pharmaceuticals LLC

Additional Topics

United States Financing Rare Diseases Regulation BioPharmaceutical

More from Rare Diseases

More from Pink Sheet

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window